We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+6.55%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$8.48B
AUM Growth
+$646M
Cap. Flow
-$773M
Cap. Flow %
-9.12%
Top 10 Hldgs %
50.85%
Holding
160
New
9
Increased
15
Reduced
10
Closed
78

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$83.8M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$82.1M
3
PFE icon
Pfizer
PFE
+$80.9M
4
GMAB icon
Genmab
GMAB
+$73.8M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$59.1M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$76.2M
2
RVMD icon
Revolution Medicines
RVMD
+$60.3M
3
PHR icon
Phreesia
PHR
+$33.8M
4
VTR icon
Ventas
VTR
+$27.4M
5
SYRE icon
Spyre Therapeutics
SYRE
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 84.65%
2 Consumer Discretionary 0%
3 Consumer Staples 0%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$1.77B 20.85%
17,248,450
– –
COGT icon
2
Cogent Biosciences
COGT
$6.68B
$348M 4.11%
9,043,903
– –
PRAX icon
3
Praxis Precision Medicines
PRAX
$8.77B
$310M 3.66%
963,351
+60,000
+7% +$18.6M
VTRS icon
4
Viatris
VTRS
$20.1B
$273M 3.22%
20,206,170
– –
UTHR icon
5
United Therapeutics
UTHR
$22.7B
$271M 3.2%
457,000
+31,007
+7% +$15.4M
RVMD icon
6
Revolution Medicines
RVMD
$39.6B
$223M 2.64%
2,297,000
-597,613
-21% -$60.3M
CELC icon
7
Celcuity
CELC
$4.31B
$196M 2.31%
1,714,000
– –
CNC icon
8
Centene
CNC
$32.8B
$194M 2.29%
5,917,091
-530,907
-8% -$21.8M
LRMR icon
9
Larimar Therapeutics
LRMR
$384M
$160M 1.89%
35,606,974
+5,000,000
+16% +$20M
BKD icon
10
Brookdale Senior Living
BKD
$3.58B
$159M 1.88%
11,637,032
– –
VERA icon
11
Vera Therapeutics
VERA
$2.76B
$150M 1.77%
3,722,100
-337,595
-8% -$14.5M
IONS icon
12
Ionis Pharmaceuticals
IONS
$8.99B
$149M 1.75%
1,979,669
– –
BCRX icon
13
BioCryst Pharmaceuticals
BCRX
$2.36B
$143M 1.69%
15,038,000
+697,000
+5% +$5.41M
INSP icon
14
Inspire Medical Systems
INSP
$1.46B
$139M 1.65%
2,703,238
+1,197,366
+80% +$83.8M
LEGN icon
15
Legend Biotech
LEGN
$4.31B
$139M 1.64%
7,687,638
+1,755,638
+30% +$33.5M
AHCO icon
16
AdaptHealth
AHCO
$1.49B
$137M 1.61%
11,477,730
– –
NAMS icon
17
NewAmsterdam Pharma
NAMS
$3.7B
$137M 1.61%
4,264,789
+100,000
+2% +$3.26M
ACHC icon
18
Acadia Healthcare
ACHC
$3.17B
$106M 1.25%
4,520,000
– –
ARWR icon
19
Arrowhead Research
ARWR
$10.5B
$98.6M 1.16%
1,573,297
-259,649
-14% -$16.4M
CPRX
20
DELISTED
Catalyst Pharmaceutical
CPRX
$97.6M 1.15%
3,943,600
-967,561
-20% -$23.1M
INDV icon
21
Indivior Pharmaceuticals
INDV
$4.79B
$94.4M 1.11%
3,097,790
-295,273
-9% -$9.75M
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.6B
$94M 1.11%
1,615,696
+1,073,676
+198% +$49.5M
PHVS icon
23
Pharvaris
PHVS
$2.44B
$88.3M 1.04%
3,126,042
– –
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$2.02B
$88.3M 1.04%
+3,779,900
New +$82.1M
TNGX icon
25
Tango Therapeutics
TNGX
$4.65B
$86.8M 1.02%
4,146,813
+1,239,867
+43% +$17.3M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2026 Portfolio in Review

As of Q1 2026, Deerfield Management held 160 positions worth $8.48B, up 8.3% from $7.83B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Deerfield Management withdrew a net $773M in Q1 2026, closing 78 positions and reducing 10 holdings. Its most notable exit was Phreesia, an estimated $33.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Syndax Pharmaceuticals worth $88.3M.

  • Deerfield Management's largest Q1 2026 buy was Syndax Pharmaceuticals: 3,779,900 shares worth $88.3M.
  • Deerfield Management added most to Inspire Medical Systems in Q1 2026, an estimated $83.8M increase.
  • Deerfield Management's biggest Q1 2026 reduction was Neurocrine Biosciences, cutting an estimated $76.2M.
  • Deerfield Management fully exited Phreesia in Q1 2026, selling an estimated $33.8M.
  • Deerfield Management's ten largest holdings make up 51% of its $8.48B portfolio in Q1 2026.
  • Deerfield Management opened 9 new positions and closed 78 in Q1 2026.
  • Deerfield Management's portfolio value rose 8.3% quarter-over-quarter to $8.48B.

Based on Deerfield Management's 13F filing for Q1 2026, filed 15 May 2026.